Literature DB >> 23790627

TALEN or Cas9 - rapid, efficient and specific choices for genome modifications.

Chuanxian Wei1, Jiyong Liu, Zhongsheng Yu, Bo Zhang, Guanjun Gao, Renjie Jiao.   

Abstract

Precise modifications of complex genomes at the single nucleotide level have been one of the big goals for scientists working in basic and applied genetics, including biotechnology, drug development, gene therapy and synthetic biology. However, the relevant techniques for making these manipulations in model organisms and human cells have been lagging behind the rapid high throughput studies in the post-genomic era with a bottleneck of low efficiency, time consuming and laborious manipulation, and off-targeting problems. Recent discoveries of TALEs (transcription activator-like effectors) coding system and CRISPR (clusters of regularly interspaced short palindromic repeats) immune system in bacteria have enabled the development of customized TALENs (transcription activator-like effector nucleases) and CRISPR/Cas9 to rapidly edit genomic DNA in a variety of cell types, including human cells, and different model organisms at a very high efficiency and specificity. In this review, we first briefly summarize the development and applications of TALENs and CRISPR/Cas9-mediated genome editing technologies; compare the advantages and constraints of each method; particularly, discuss the expected applications of both techniques in the field of site-specific genome modification and stem cell based gene therapy; finally, propose the future directions and perspectives for readers to make the choices.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23790627     DOI: 10.1016/j.jgg.2013.03.013

Source DB:  PubMed          Journal:  J Genet Genomics        ISSN: 1673-8527            Impact factor:   4.275


  48 in total

1.  Highly efficient genome modifications mediated by CRISPR/Cas9 in Drosophila.

Authors:  Zhongsheng Yu; Mengda Ren; Zhanxiang Wang; Bo Zhang; Yikang S Rong; Renjie Jiao; Guanjun Gao
Journal:  Genetics       Date:  2013-07-05       Impact factor: 4.562

2.  RNA-guided nucleases: a new era for engineering the genomes of model and nonmodel organisms.

Authors:  Kent G Golic
Journal:  Genetics       Date:  2013-10       Impact factor: 4.562

Review 3.  Imaging methodologies for systems biology.

Authors:  Sarah E Smith; Brian D Slaughter; Jay R Unruh
Journal:  Cell Adh Migr       Date:  2014-11-01       Impact factor: 3.405

4.  Phenotyping analysis of p53 knockout mice produced by gene editing and comparison with conventional p53 knockout mice.

Authors:  Ukjin Kim; C-Yoon Kim; Hanseul Oh; Ji Min Lee; Seo-Na Chang; Bokyeong Ryu; Jin Kim; Han-Woong Lee; Jae-Hak Park
Journal:  Genes Genomics       Date:  2019-04-15       Impact factor: 1.839

Review 5.  Characterization of noncoding regulatory DNA in the human genome.

Authors:  Ran Elkon; Reuven Agami
Journal:  Nat Biotechnol       Date:  2017-08-08       Impact factor: 54.908

Review 6.  HTS/HCS to screen molecules able to maintain embryonic stem cell self-renewal or to induce differentiation: overview of protocols.

Authors:  Genesia Manganelli; Ugo Masullo; Stefania Filosa
Journal:  Stem Cell Rev Rep       Date:  2014-12       Impact factor: 5.739

Review 7.  Applications of TALENs and CRISPR/Cas9 in human cells and their potentials for gene therapy.

Authors:  Jingwen Niu; Bin Zhang; Hu Chen
Journal:  Mol Biotechnol       Date:  2014-08       Impact factor: 2.695

8.  Non-coding RNA: a new frontier in regulatory biology.

Authors:  Xiang-Dong Fu
Journal:  Natl Sci Rev       Date:  2014-06-01       Impact factor: 17.275

Review 9.  Small molecules targeting microRNA for cancer therapy: Promises and obstacles.

Authors:  Di Wen; Michael Danquah; Amit Kumar Chaudhary; Ram I Mahato
Journal:  J Control Release       Date:  2015-08-06       Impact factor: 9.776

Review 10.  The application of CRISPR-Cas9 genome editing in Caenorhabditis elegans.

Authors:  Suhong Xu
Journal:  J Genet Genomics       Date:  2015-06-26       Impact factor: 4.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.